


# U.S. Homeland Security Pharmaceuticals & Chemicals R&D Programs & Funding Opportunities

## 2006 - 2010



- 
- 
- 
- 
- 

## Table of Contents

|  |           |
|--|-----------|
| <b>1. Executive Summary .....</b>  | <b>31</b> |
| 1.1. Introduction .....  | 31        |
| 1.2. Basic Scenario Assumptions.....   | 33        |
| 1.3. Methodology .....   | 33        |
| 1.4. Major Research Findings .....   | 35        |
| 1.4.1. U.S. HLS Pharmaceuticals R&D Budget Forecast –<br>2006–2010 .....                   | 36        |
| 1.4.2. U.S. HLS Pharmaceuticals R&D Market Forecast –<br>2006–2010 .....                   | 38        |
| 1.5. Major Research Conclusions .....  | 40        |
| <b>2. U.S. HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006 – 2010.....</b>        | <b>42</b> |
| 2.1. U.S. Homeland Security R&D Structure.....   | 42        |
| 2.1.1. Definitions .....   | 45        |
| 2.2. U.S. HLS Pharmaceuticals R&D – Participating Agencies & Funding –<br>2006–2010 .....  | 47        |
| 2.3. U.S. HLS Pharmaceuticals R&D Outlay – Overview 2006 – 2010 .....                      | 48        |
| 2.4. U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast –<br>2006–2010 .....      | 51        |
| 2.5. U.S. HLS Pharmaceuticals R&D Funding Opportunities Drivers –<br>2006–2010 .....       | 56        |
| 2.6. U.S. HLS Pharmaceuticals R&D Funding Opportunities Inhibitors –<br>2006–2010 .....    | 56        |
| <b>3. DHHS – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010.....</b>        | <b>57</b> |
| 3.1. NIH (DHHS) – Homeland Security Mission .....  | 57        |
| 3.2. CDC (DHHS) – Homeland Security Mission .....  | 58        |
| 3.3. FDA (DHHS) – Homeland Security Mission .....  | 59        |
| 3.4. DHHS – HLS Pharmaceuticals R&D Program Summary & Budget<br>Forecast – 2006–2010 ..... | 60        |
| 3.4.1. DHHS – HLS Pharmaceuticals R&D Budget Forecast by<br>Application – 2006–2010 .....  | 61        |
| 3.5. DHHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast –<br>2006–2010 .....    | 64        |
| 3.6. DHHS – HLS Pharmaceuticals R&D Funding Opportunities Drivers –<br>2006–2010 .....     | 68        |
| 3.7. DHHS – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors –<br>2006–2010 .....  | 68        |
| <b>4. DOD – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010.....</b>         | <b>69</b> |
| 4.1. DOD – General Structure of R&D Budget & Fund Allocations .....                        | 69        |
| 4.2. DOD – R&D Policy Making Hierarchy .....   | 70        |
| 4.3. U.S. ARMY – R&D Funding Agencies.....   | 72        |
| 4.3.1. U.S. ARMY Research Office (ARO) .....   | 72        |
| 4.3.2. U.S. ARMY Research Laboratory (ARL) .....   | 73        |
| 4.4. DOD – Defense Advanced Research Projects Agency (DARPA) .....                         | 74        |
| 4.5. DOD – Chemical and Biological Defense Program (CBDP).....                             | 74        |
| 4.6. DOD – HLS Pharmaceuticals R&D Program Summary & Budget<br>Forecast – 2006–2010 .....  | 76        |

|           |  |            |
|-----------|--|------------|
| 4.6.1.    | DOD – HLS Pharmaceuticals R&D Budget Forecast by Application – 2006–2010 .....     | 79         |
| 4.6.2.    | DOD – HLS Pharmaceuticals R&D Budget Forecast by Agency – 2006–2010 .....          | 81         |
| 4.7.      | DOD – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....     | 84         |
| 4.8.      | DOD – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....      | 87         |
| 4.9.      | DOD – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....   | 88         |
| <b>5.</b> | <b>DHS – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010 .....</b>   | <b>89</b>  |
| 5.1.      | Outline and Resources.....   | 89         |
| 5.2.      | DHS – Science & Technology Division (S&T) .....                                    | 89         |
| 5.3.      | S&T Directorate – Major Groups .....   | 92         |
| 5.3.1.    | DHS – Office of Programs Plans & Budgets (PPB) .....                               | 92         |
| 5.3.2.    | DHS – Homeland Security Advanced Research Projects Agency (HSARPA) .....           | 93         |
| 5.3.3.    | DHS – Office of R&D.....   | 94         |
| 5.3.4.    | DHS – Office of Systems Engineering and Development (SED) .....                    | 95         |
| 5.4.      | DHS – HLS Pharmaceuticals R&D Program Summary & Budget Forecast – 2006–2010 .....  | 97         |
| 5.5.      | DHS – Pharmaceuticals R&D Budget Forecast by Application – 2006–2010 .....         | 99         |
| 5.6.      | DHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....     | 101        |
| 5.6.1.    | Allocation to Private, Academia & Government Sectors – 2006 – 2010 .....           | 103        |
| 5.7.      | DHS – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....      | 105        |
| 5.8.      | DHS – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....   | 106        |
| <b>6.</b> | <b>DOE – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010 .....</b>   | <b>107</b> |
| 6.1.      | DOE – HLS R&D Sources.....   | 107        |
| 6.2.      | DOE – HLS Pharmaceuticals R&D Program Summary & Budget Forecast – 2006–2010 .....  | 108        |
| 6.3.      | DOE – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....     | 110        |
| 6.4.      | DOE – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....      | 114        |
| 6.5.      | DOE – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....   | 114        |
| <b>7.</b> | <b>USDA – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010....</b>    | <b>115</b> |
| 7.1.      | USDA – HLS R&D Sources .....   | 115        |
| 7.2.      | USDA – HLS Pharmaceuticals R&D Program Summary & Budget Forecast – 2006–2010 ..... | 116        |
| 7.3.      | USDA – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....    | 118        |

|            |  |            |
|------------|--|------------|
| 7.4.       | USDA – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....   | 121        |
| 7.5.       | USDA – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....  | 122        |
| <b>8.</b>  | <b>EPA – HLS Pharmaceuticals R&amp;D Funding Opportunities – 2006–2010.....</b>  | <b>123</b> |
| 8.1.       | EPA – HLS R&D Sources .....  | 123        |
| 8.2.       | EPA – HLS Pharmaceuticals R&D Program Summary & Budget Forecast – 2006–2010 .....  | 124        |
| 8.2.1.     | EPA – HLS Pharmaceuticals R&D Budget Forecast by Application – 2006–2010 .....   | 124        |
| 8.3.       | EPA – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....   | 125        |
| 8.4.       | EPA – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....  | 129        |
| 8.5.       | EPA – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....   | 129        |
| <b>9.</b>  | <b>Biological Therapeutics – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b> | <b>130</b> |
| 9.1.       | Summary & Outlook .....  | 130        |
| 9.2.       | Biological Therapeutics – HLS R&D Budget Forecast by Major Departments – 2006–2010 .....                                   | 131        |
| 9.2.1.     | DHHS – Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                   | 133        |
| 9.2.2.     | DOD – Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                    | 134        |
| 9.3.       | Biological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006 – 2010 .....                       | 135        |
| 9.4.       | Biological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....                          | 139        |
| 9.5.       | Biological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....                       | 139        |
| 9.6.       | NIH & NIAID (DHHS) – Biological Therapeutics HLS Pharmaceuticals R&D Programs .....  | 140        |
| 9.6.1.     | Category A Agents: Development of Biomedical Measures .....  | 140        |
| 9.7.       | DARPA (DOD) – Biological Therapeutics HLS Pharmaceuticals R&D Programs .....   | 143        |
| 9.7.1.     | Unconventional Therapeutics .....  | 143        |
| 9.8.       | CBDP (DOD) – Biological Therapeutics HLS Pharmaceuticals R&D Programs .....  | 144        |
| 9.8.1.     | Project TB1 Medical Biological Defense (Basic Research) – Therapeutics .....   | 144        |
| 9.8.2.     | Project TB2 Medical Biological Defense (Applied Research) – Therapeutics .....   | 145        |
| 9.8.3.     | Project TB3 Medical Biological Defense (ATD) .....   | 146        |
| <b>10.</b> | <b>Vaccines – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b>                | <b>147</b> |
| 10.1.      | Summary & Outlook .....  | 147        |

|            |  |            |
|------------|--|------------|
| 10.2.      | Vaccines – HLS Pharmaceuticals R&D Budget Forecast by Major Departments – 2006–2010.....                                 | 148        |
| 10.2.1.    | DHHS – Vaccines HLS Pharmaceuticals R&D.....   | 150        |
| 10.2.2.    | DOD – Vaccines HLS Pharmaceuticals R&D.....  | 151        |
| 10.3.      | Vaccines – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....                                      | 152        |
| 10.4.      | Vaccines – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010.....  | 156        |
| 10.5.      | Vaccines – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010.....                                     | 157        |
| 10.6.      | NIH & NIAID (DHHS) – Vaccines HLS Pharmaceuticals R&D Programs .....   | 158        |
| 10.6.1.    | Category A Agents: Development of Biomedical Measures .....  | 158        |
| 10.6.2.    | Category B and C Priority Pathogens and Toxins .....   | 160        |
| 10.7.      | ARMY (DOD) – Vaccines HLS Pharmaceuticals R&D Programs .....   | 161        |
| 10.7.1.    | Medical Technology - Infectious Diseases .....   | 161        |
| 10.7.2.    | Medical Advanced Technology - Infectious Diseases .....  | 163        |
| 10.8.      | CBDP (DOD) – Vaccines HLS Pharmaceuticals R&D Programs.....  | 164        |
| 10.8.1.    | Project TB1 Medical Biological Defense (Basic Research) – Vaccines.....  | 164        |
| 10.8.2.    | Project TB2 Medical Biological Defense (Applied Research) – Vaccines.....  | 164        |
| 10.8.3.    | Project TB3 Medical Biological Defense (ATD) – Vaccines.....   | 165        |
| 10.8.4.    | Project MB4 Medical Biological Defense (ACD&P) – Vaccines.....   | 166        |
| 10.8.5.    | Project MB5 Medical Biological Defense (SDD) – Vaccines.....   | 168        |
| <b>11.</b> | <b>Chemical Therapeutics – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b> | <b>171</b> |
| 11.1.      | Summary & Outlook.....   | 171        |
| 11.2.      | DOD – Chemical Therapeutics – HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                  | 172        |
| 11.3.      | Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006 – 2010.....                        | 173        |
| 11.4.      | Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006 – 2010.....                         | 178        |
| 11.5.      | Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006 – 2010 .....                     | 178        |
| 11.6.      | CBDP (DOD) – Chemical Therapeutics – HLS Pharmaceuticals R&D Programs .....  | 179        |
| 11.6.1.    | Project TC1 Medical Chemical Defense (Basic Research) – Therapeutics .....   | 179        |
| 11.6.2.    | Project TC2 Medical Chemical Defense (Applied Research) – Therapeutics .....   | 182        |
| 11.6.3.    | Project TC2 Medical Chemical Defense (Applied Research) – Pretreatments.....   | 183        |

|            |  |            |
|------------|--|------------|
| 11.6.4.    | Project TC3 Medical Chemical Defense (ATD) – Therapeutics .....  | 184        |
| 11.6.5.    | Project TC3 Medical Chemical Defense (ATD) – Pretreatments.....  | 187        |
| 11.6.6.    | Project MC4 Medical Chemical Defense (ACD&P) – Therapeutics .....  | 188        |
| 11.6.7.    | Project MC4 Medical Chemical Defense (ACD&P) .....   | 189        |
| <b>12.</b> | <b>Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b> | <b>191</b> |
| 12.1.      | Summary & Outlook .....  | 191        |
| 12.2.      | Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D by Major Departments Forecast – 2006–2010.....                           | 194        |
| 12.2.1.    | NIH (DHHS) – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                           | 194        |
| 12.2.2.    | DOD – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                  | 195        |
| 12.2.3.    | DOE – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                  | 196        |
| 12.3.      | Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....                         | 198        |
| 12.4.      | Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010.....                           | 202        |
| 12.5.      | Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....                       | 203        |
| 12.6.      | NIH (DHHS) – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Programs .....  | 204        |
| 12.6.1.    | Therapeutics for Radiation Damage.....   | 204        |
| 12.7.      | CBDP (DOD) – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Programs .....  | 205        |
| 12.7.1.    | Project TR2 Medical Radiological Defense (Applied Research).....   | 205        |
| 12.7.2.    | Project TR3 Medical Radiological Defense (ATD).....  | 205        |
| 12.7.3.    | Project MR4 Medical Radiological Defense .....   | 207        |
| 12.8.      | DOE – Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Programs.....  | 208        |
| 12.8.1.    | Low Dose Radiation research .....  | 208        |
| <b>13.</b> | <b>Decontamination – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b>                   | <b>211</b> |
| 13.1.      | Summary & Outlook .....  | 211        |
| 13.2.      | Decontamination – HLS Pharmaceuticals R&D by Major Departments Forecast – 2006–2010 .....  | 212        |
| 13.2.1.    | EPA – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....  | 214        |
| 13.2.2.    | DOD – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....  | 214        |
| 13.2.3.    | DHS – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....  | 215        |

|            |  |            |
|------------|--|------------|
| 13.2.4.    | DOE – Decontamination HLS Pharmaceuticals R&D Budget<br>Forecast – 2006–2010 .....                                 | 216        |
| 13.2.5.    | TSWG – Decontamination HLS Pharmaceuticals R&D<br>Budget Forecast – 2006–2010 .....                                | 217        |
| 13.3.      | Decontamination – HLS Pharmaceuticals R&D Funding Opportunities<br>Forecast – 2006–2010 .....                      | 219        |
| 13.4.      | Decontamination – HLS Pharmaceuticals R&D Funding Opportunities<br>Drivers – 2006–2010.....                        | 223        |
| 13.5.      | Decontamination HLS Pharmaceuticals R&D Funding Opportunities<br>Inhibitors – 2006–2010.....                       | 223        |
| 13.6.      | DHS – Decontamination HLS Pharmaceuticals R&D Programs .....   | 224        |
| 13.6.1.    | Response and Recovery .....  | 224        |
| 13.6.2.    | Decontamination of Porous Surfaces after a Radiological<br>Attack .....  | 224        |
| 13.6.3.    | Expedient Mitigation of a Radiological Release .....   | 224        |
| 13.7.      | DARPA (DOD) – Decontamination HLS Pharmaceuticals R&D<br>Programs .....  | 225        |
| 13.7.1.    | Immune Buildings.....  | 225        |
| 13.7.2.    | External protection .....  | 226        |
| 13.8.      | CBDP (DOD) – Decontamination HLS Pharmaceuticals R&D<br>Programs .....   | 228        |
| 13.8.1.    | Project CB1 – Decontamination .....  | 228        |
| 13.8.2.    | Project CB2 – Decontamination .....  | 228        |
| 13.8.3.    | Project CB3 Biological Defense (ATD) – Decontamination .....   | 229        |
| 13.8.4.    | Project DE4 Decontamination Systems (ACD&P).....   | 230        |
| 13.8.5.    | Project DE5 Decontamination Systems (SDD).....   | 230        |
| 13.9.      | ARMY (DOD) – Decontamination HLS Pharmaceuticals R&D<br>Programs .....   | 233        |
| 13.9.1.    | Environmental Quality Technology.....  | 233        |
| 13.10.     | DOE – Decontamination HLS Pharmaceuticals R&D Programs .....   | 237        |
| 13.10.1.   | Environmental Remediation Science Research .....   | 237        |
| 13.11.     | EPA – Decontamination HLS Pharmaceuticals R&D Programs.....  | 239        |
| 13.11.1.   | Water Infrastructure Decontamination.....  | 239        |
| 13.11.2.   | Threat and Consequence Assessment .....  | 239        |
| 13.11.3.   | Nonstandard Methods .....  | 239        |
| 13.11.4.   | Decontamination for Buildings, Large Structures, and<br>Outdoor Areas.....   | 240        |
| 13.11.5.   | Toxicity, Infectivity, and Mechanism of Action .....   | 240        |
| 13.12.     | TSWG – Decontamination HLS Pharmaceuticals R&D Programs .....  | 241        |
| 13.12.1.   | Statistical Design Tool for Sampling Contaminated<br>Buildings.....  | 241        |
| 13.12.2.   | Decontamination .....  | 241        |
| <b>14.</b> | <b>Diagnostics – HLS Pharmaceuticals R&amp;D Programs and Funding<br/>Opportunities Forecast – 2006–2010 .....</b> | <b>242</b> |
| 14.1.      | Summary & Outlook.....   | 242        |
| 14.2.      | Diagnostics – HLS Pharmaceuticals R&D by Major Departments<br>Budget Forecast – 2006–2010.....                     | 243        |

|            |   |            |
|------------|---|------------|
| 14.2.1.    | DHHS – Diagnostics HLS Pharmaceuticals R&D Budget<br>Forecast – 2006–2010 .....   | 245        |
| 14.2.2.    | DOD – Diagnostics HLS Pharmaceuticals R&D Budget<br>Forecast – 2006–2010 .....  | 245        |
| 14.3.      | Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities<br>Forecast – 2006–2010 .....   | 247        |
| 14.4.      | Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities<br>Drivers – 2006–2010.....   | 250        |
| 14.5.      | Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities<br>Inhibitors – 2006–2010.....  | 251        |
| 14.6.      | NIH & NIAID (DHHS) – Diagnostics HLS Pharmaceuticals R&D<br>Programs .....  | 252        |
| 14.6.1.    | Category A Agents: Development of Diagnostic Measures.....  | 252        |
| 14.7.      | ARMY (DOD) – Diagnostics HLS Pharmaceuticals R&D Programs .....   | 252        |
| 14.7.1.    | Infectious Diseases .....   | 252        |
| 14.8.      | DARPA (DOD) – Diagnostics HLS Pharmaceuticals R&D Programs.....   | 253        |
| 14.8.1.    | Advanced Diagnostics.....   | 253        |
| 14.9.      | CBDP (DOD) – Diagnostics HLS Pharmaceuticals R&D Programs .....   | 255        |
| 14.9.1.    | Project TB1 Medical Biological Defense (Basic Research) –<br>Diagnostics.....   | 255        |
| 14.9.2.    | Project TB2 Medical Biological Defense (Applied Research) –<br>Diagnostics.....   | 255        |
| 14.9.3.    | Project TB3 Medical Biological Defense (ATD) –<br>Diagnostics.....  | 256        |
| 14.9.4.    | Project MB5 Medical Biological Defense (SDD) –<br>Diagnostics.....  | 257        |
| 14.9.5.    | Project TC1 Medical Chemical Defense (Basic Research) –<br>Diagnostics.....   | 258        |
| 14.9.6.    | Project TC2 Medical Chemical Defense (Applied Research) –<br>Diagnostics.....   | 259        |
| 14.9.7.    | Project TC3 Medical Chemical Defense (ATD) – Diagnostics....  | 260        |
| <b>15.</b> | <b>Food Protection Treatments – HLS Pharmaceuticals R&amp;D Programs<br/>and Funding Opportunities Forecast – 2006–2010 .....</b> | <b>262</b> |
| 15.1.      | Summary & Outlook .....   | 262        |
| 15.2.      | Food Protection Treatments – HLS Pharmaceuticals R&D by Major<br>Departments Forecast – 2006–2010.....                            | 263        |
| 15.2.1.    | DHHS – Food Protection Treatments HLS Pharmaceuticals<br>R&D Forecast – 2006–2010.....  | 265        |
| 15.2.2.    | USDA – Food Protection Treatments HLS Pharmaceuticals<br>R&D Forecast – 2006–2010.....  | 266        |
| 15.2.3.    | DHS – Food Protection Treatments HLS Pharmaceuticals<br>R&D Forecast – 2006–2010.....   | 267        |
| 15.3.      | Food Protection Treatments – HLS Pharmaceuticals R&D Funding<br>Opportunities Forecast – 2006–2010 .....                          | 268        |
| 15.4.      | Food Protection Treatments – HLS Pharmaceuticals R&D Funding<br>Opportunities Drivers – 2006–2010.....                            | 273        |
| 15.5.      | Food Protection Treatments – HLS Pharmaceuticals R&D Funding<br>Opportunities Inhibitors – 2006–2010 .....                        | 273        |

|            |   |            |
|------------|---|------------|
| 15.6.      | DHS – Food Protection Treatments HLS Pharmaceuticals R&D Programs .....   | 274        |
| 15.6.1.    | Agriculture .....   | 274        |
| 15.7.      | FDA (DHHS) – Food Protection Treatments HLS Pharmaceuticals R&D Programs .....  | 274        |
| 15.7.1.    | Food Defense Research .....   | 274        |
| 15.8.      | USDA – Food Protection Treatments HLS Pharmaceuticals R&D Programs .....  | 275        |
| 15.8.1.    | Livestock Protection .....  | 275        |
| 15.9.      | NIH (DHHS) – Food Protection Treatments HLS Pharmaceuticals R&D Programs .....  | 276        |
| 15.9.1.    | Food and Water-Borne Diseases .....   | 276        |
| <b>16.</b> | <b>Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&amp;D Programs and Funding Opportunities Forecast – 2006–2010 .....</b> | <b>277</b> |
| 16.1.      | Summary & Outlook .....   | 277        |
| 16.2.      | Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Budget Forecast by Major Departments– 2006–2010 .....                    | 278        |
| 16.2.1.    | DHHS – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                   | 280        |
| 16.2.2.    | DOD – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                    | 280        |
| 16.2.3.    | DHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                    | 281        |
| 16.2.4.    | NSF – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast – 2006–2010 .....                                    | 283        |
| 16.3.      | Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Funding Opportunities Forecast – 2006–2010 .....                         | 284        |
| 16.4.      | Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Funding Opportunities Drivers – 2006–2010 .....                          | 288        |
| 16.5.      | Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Funding Opportunities Inhibitors – 2006–2010 .....                       | 289        |
| 16.6.      | DHS – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs .....   | 290        |
| 16.6.1.    | Threat Awareness and Characterization .....   | 290        |
| 16.6.2.    | Forensics.....  | 290        |
| 16.7.      | NIH & NIAID (DHHS) – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs.....   | 291        |
| 16.7.1.    | Sequencing of Microorganisms .....  | 291        |
| 16.7.2.    | Developing Research Tools .....   | 291        |
| 16.7.3.    | Understanding, Assessing, and Enhancing Host Immunity .....   | 291        |
| 16.8.      | CDC (DHHS) – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs .....  | 292        |
| 16.8.1.    | Reduce the Spread of Anti-Microbial Resistance .....  | 292        |
| 16.9.      | DARPA (DOD) – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs .....   | 292        |
| 16.9.1.    | Biological Adaptation, Assembly, and Manufacture .....  | 292        |
| 16.9.2.    | Nanostructure in Biology .....  | 294        |

|   |            |
|---|------------|
| 16.10. CBDP (DOD) – Treatment for Emerging Biochemical Threats HLS<br>Pharmaceuticals R&D Programs .....        | 295        |
| 16.10.1. Project CB1 Biological Defense (Basic Research) – Other .....  | 295        |
| 16.10.2. Project TB1 Medical Biological Defense (Basic Research) –<br>Multi-Agent Medical Countermeasures ..... | 296        |
| 16.10.3. Project TB2 Medical Biological Defense (Applied Research) –<br>Emerging Threats.....                   | 296        |
| 16.10.4. Project TB3 Medical Biological Defense (ATD) – Emerging<br>Threats .....                               | 297        |
| 16.10.5. Project MB5 Medical Biological Defense (SDD) – Critical<br>Reagents Program (CRP) .....                | 298        |
| 16.10.6. Project TC1 Medical Chemical Defense (Basic Research) –<br>Emerging Threats.....                       | 298        |
| 16.10.7. Project TC2 Medical Chemical Defense (Applied Research) –<br>Emerging Threats.....                     | 300        |
| 16.10.8. Project TC3 Medical Chemical Defense (ATD) – Emerging<br>Threats .....                                 | 301        |
| 16.10.9. Project CB2 Chemical Defense (Applied Research) –<br>Threat Agent Sciences .....                       | 302        |
| 16.11. NSF – Treatment for Emerging Biochemical Threats HLS<br>Pharmaceuticals R&D Programs .....               | 303        |
| 16.11.1. Fundamental Research to Enhance Homeland Security.....   | 303        |
| <b>17. Investing In HLS Technology .....</b>  | <b>305</b> |
| 17.1. A Word of Caution.....  | 305        |
| 17.2. HLS Industry Experts .....  | 305        |
| 17.3. Competitive Intelligence .....  | 306        |
| 17.4. A Second Opinion .....  | 306        |
| <b>Appendix A: The Homeland Security Federal R&amp;D Infrastructure .....</b>                                   | <b>307</b> |
| A.1. SBIR (Small Business Innovations Research) R&D Funding.....  | 307        |
| A.2. STTR (Small Business Technology Transfer Program) R&D Funding.....   | 312        |

## List of Figures

### 1. Executive Summary

|  |    |
|--|----|
| Figure 1 – U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [\$B] – 2006–2010.....                    | 37 |
| Figure 2 – U.S. HLS Pharmaceuticals R&D Budget Forecast by Application Share – 2004, 2006 & 2010 .....           | 37 |
| Figure 3 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$B] – 2006–2010 .....         | 39 |
| Figure 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 40 |

### 2. U.S. HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010

|  |    |
|--|----|
| Figure 5 - Overview of Entire Homeland Security and Homeland Defense Infrastructure .....                        | 44 |
| Figure 6 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency [\$B] – 2006–2010.....                 | 50 |
| Figure 7 –Federal HLS Pharmaceuticals R&D Budget Forecast by Agency Share – 2004, 2006 & 2010 .....              | 51 |
| Figure 8 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$B] – 2006–2010 .....         | 53 |
| Figure 9 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 53 |
| Figure 10 – U.S. HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$B] – 2006–2010 .....   | 54 |
| Figure 11 – U.S. HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$B] – 2006–2010 .....  | 54 |
| Figure 12 – U.S. HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [\$B] – 2006–2010 .....       | 55 |

### 3. DHHS – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010

|   |    |
|---|----|
| Figure 13 - DHHS – HLS Pharmaceuticals R&D Budget Forecast by Application [\$B] – 2006–2010.....                    | 63 |
| Figure 14 - DHHS – HLS Pharmaceuticals R&D Budget Forecast by Application Share – 2004, 2006 & 2010 .....           | 63 |
| Figure 15 - DHHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$B] – 2006–2010 .....         | 65 |
| Figure 16 - DHHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 66 |
| Figure 17 - DHHS – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010.....     | 66 |
| Figure 18 - DHHS – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010.....    | 67 |
| Figure 19 - DHHS – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 67 |

### 4. DOD – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010

|  |    |
|--|----|
| Figure 20 - DOD – R&D Oversight and Funding Allocation .....                                       | 71 |
| Figure 21 - DOD – Historical Trends in Defense R&D [\$B] – 2000 – 2006.....                        | 77 |
| Figure 22 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Application [\$M] – 2006–2010.....    | 80 |
| Figure 23 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Application – 2004, 2006 & 2010 ..... | 81 |

|  |    |
|--|----|
| Figure 24 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Agency [\$M] – 2006–2010.....                         | 83 |
| Figure 25 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Agency Share – 2004, 2006 & 2010 .....                | 83 |
| Figure 26 - DOD – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 85 |
| Figure 27 - DOD – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 85 |
| Figure 28 - DOD – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010.....     | 86 |
| Figure 29 - DOD – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010.....    | 86 |
| Figure 30 - DOD – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 87 |

## **5. DHS – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

|  |     |
|--|-----|
| Figure 31 - DHS – Science and Technology Division (S&T) – Organizational Chart.....                                | 91  |
| Figure 32 - DHS – HLS Pharmaceuticals R&D Budget Forecast by Application [\$B] – 2006–2010.....                    | 100 |
| Figure 33 - DHS – HLS Pharmaceuticals R&D Budget Forecast by Application Share – 2004, 2006 & 2010 .....           | 100 |
| Figure 34 - DHS –HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$B] – 2006–2010 .....          | 102 |
| Figure 35 - DHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 103 |
| Figure 36 - DHS – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010.....     | 104 |
| Figure 37 - DHS – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010.....    | 104 |
| Figure 38 - DHS – HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [\$M] – 2006–2010.....         | 105 |

## **6. DOE – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

|  |     |
|--|-----|
| Figure 39 - DOE – HLS Pharmaceuticals R&D Funding Summary Forecast [\$M] – 2006–2010.....                          | 109 |
| Figure 40 - DOE – HLS Pharmaceuticals R&D Budget Forecast by Application Share – 2004, 2006 & 2010 .....           | 110 |
| Figure 41 - DOE – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 111 |
| Figure 42 - DOE – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 112 |
| Figure 43 - DOE – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010.....     | 112 |
| Figure 44 - DOE – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010.....    | 113 |
| Figure 45 - DOE – HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [\$M] – 2006–2010.....         | 113 |

## **7. USDA – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

|   |     |
|---|-----|
| Figure 46 - USDA – Food and Water Treatment R&D Budget Forecast [\$B] – 2006–2010.....                      | 116 |
| Figure 47 - USDA – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... | 119 |

|   |     |
|---|-----|
| Figure 48 - USDA – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 119 |
| Figure 49 - USDA – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 120 |
| Figure 50 - USDA – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 120 |
| Figure 51 - USDA – HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [\$M] – 2006–2010 .....        | 121 |

**8. EPA – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

|   |     |
|---|-----|
| Figure 52 - EPA – Decontamination R&D Budget Forecast [\$M] – 2006–2010 .....                                     | 125 |
| Figure 53 - EPA –HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 126 |
| Figure 54 - EPA –HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 127 |
| Figure 55 - EPA –HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 127 |
| Figure 56 - EPA – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....  | 128 |
| Figure 57 - EPA – HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [\$M] – 2006–2010 .....       | 128 |

**9. Biological Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Figure 58 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 .....             | 132 |
| Figure 59 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share – 2004, 2006 & 2010 .....     | 132 |
| Figure 60 - DHHS – Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                           | 133 |
| Figure 61 - DOD – Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                            | 134 |
| Figure 62 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 136 |
| Figure 63 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 136 |
| Figure 64 - Biological Therapeutics HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 137 |
| Figure 65 - Biological Therapeutics HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 137 |
| Figure 66 - Biological Therapeutics HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 138 |
| Figure 67 - Unconventional Therapeutics – Program Funding [\$M] – 2004–2007 .....  | 143 |
| Figure 68 - Project TB1 Medical Biological Defense (Basic Research) Therapeutics – Program Funding [\$M] – 2004 – 2010 .....         | 144 |
| Figure 69 - Project TB2 Medical Biological Defense (Applied Research) Therapeutics – Program Funding [\$M] – 2004–2007 .....         | 145 |
| Figure 70 - Project TB3 Medical Biological Defense (ATD) – Program Funding [\$M] – 2004–2007 .....                                   | 146 |

**10. Vaccines – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Figure 71 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$B] – 2006–2010.....                           | 149 |
| Figure 72 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share – 2004, 2006 & 2010 .....                  | 149 |
| Figure 73 - DHHS – Vaccines HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010.....   | 150 |
| Figure 74 - DOD – Vaccines HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010.....  | 151 |
| Figure 75 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$B] – 2006–2010 .....                      | 153 |
| Figure 76 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010.....               | 153 |
| Figure 77 - Vaccines HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010.....                  | 154 |
| Figure 78 - Vaccines HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010.....                 | 155 |
| Figure 79 - Vaccines HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....              | 155 |
| Figure 80 - Scrub Typhus Vaccine – Program Funding [\$M] – 2004 – 4007 .....   | 161 |
| Figure 81 - Vaccines against Dengue Fever, Meningitis and Hemorrhagic Fevers – Program Funding [\$M] – 2004–2007 .....             | 162 |
| Figure 82 - Dengue, Meningitis and Hemorrhagic Fever with Renal Syndrome (HFRS) Vaccines – Program Funding [\$M] – 2004–2010 ..... | 163 |
| Figure 83 - Project TB1 Medical Biological Defense (Basic Research) – Vaccines – Program funding [\$M] – 2004–2007 .....           | 164 |
| Figure 84 - Project TB2 Medical Biological Defense (Applied Research) – Vaccines – Program Funding [\$M] – 2004–2007 .....         | 165 |
| Figure 85 - Project TB3 Medical Biological Defense (Applied Research) – Vaccines – Program Funding [\$M] – 2004–2007 .....         | 166 |
| Figure 86 - Project MB4 Medical Biological Defense (ACD&P) – Botulinum Vaccine – Program Funding [\$M] – 2004–2006.....            | 167 |
| Figure 87 - Project MB4 Medical Biological Defense (ACD&P) – Encephalitis Vaccine – Program Funding [\$M] – 2004–2006 .....        | 167 |
| Figure 88 - Project MB4 Medical Biological Defense (ACD&P) – Plague Vaccine – Program Funding [\$M] – 2004–2006.....               | 168 |
| Figure 89 - Project MB5 Medical Biological Defense (SDD) – Botulinum Vaccine – Program Funding [\$M] – 2004–2007.....              | 169 |
| Figure 90 - Project MB5 Medical Biological Defense (SDD) – Plague Vaccine – Program Funding [\$M] – 2004–2007.....                 | 170 |

## 11. Chemical Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010

|   |     |
|---|-----|
| Figure 91 - DOD – Chemical Therapeutics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010.....                              | 172 |
| Figure 92 - Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010.....         | 174 |
| Figure 93 - Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010..... | 174 |
| Figure 94 - Chemical Therapeutics – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 175 |
| Figure 95 - Chemical Therapeutics – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....  | 176 |

|  |     |
|--|-----|
| Figure 96 - Chemical Therapeutics – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....             | 177 |
| Figure 97 - Project TC1 Medical Chemical Defense (Basic Research) – Therapeutics – Program Funding [\$M] – 2004–2007 .....                       | 179 |
| Figure 98 - Nerve Agent Defense, Neuroprotection – Program Funding [\$M] – 2004–2007.....  | 180 |
| Figure 99 - Vesicant Agent Defense, Vesicant Medical Countermeasures– Program Funding [\$M] – 2004–2007 .....                                    | 181 |
| Figure 100 - Chemical Warfare Agent Defense, Inhalation Therapeutics – Program Funding [\$M] – 2004–2007 .....                                   | 182 |
| Figure 101 - Project TC2 Medical Chemical Defense (Applied Research) – Therapeutics – Program Funding [\$M] – 2004–2007 .....                    | 183 |
| Figure 102 - Project TC2 Medical Chemical Defense (Applied Research) – Pretreatments – Program Funding [\$M] – 2004–2007 .....                   | 183 |
| Figure 103 - Project TC3 Medical Chemical Defense (ATD) – Therapeutics – Program Funding [\$M] – 2004–2007 .....                                 | 184 |
| Figure 104 - Project TC3 Medical Chemical Defense (ATD) – Therapeutics – Anti-Convulsants – Program Funding [\$M] – 2004–2007.....               | 185 |
| Figure 105 - Project TC3 Medical Chemical Defense (ATD) – Neuroprotectors – Program Funding [\$M] – 2004–2007 .....                              | 185 |
| Figure 106 - Project TC3 Medical Chemical Defense (ATD) – Vesicant Agent Defense – Program Funding [\$M] – 2004–2007 .....                       | 186 |
| Figure 107 - Project TC3 Medical Chemical Defense (ATD) – Therapeutics – Skin and Wound Decontamination – Program Funding [\$M] – 2004–2007..... | 187 |
| Figure 108 - Project TC3 Medical Chemical Defense (ATD) – Pretreatments – Program Funding [\$M] – 2004–2007 .....                                | 188 |
| Figure 109 - Project MC4 Medical Chemical Defense (ACD&P) – Therapeutics – Program Funding [\$M] – 2004–2007 .....                               | 189 |
| Figure 110 - Project MC4 Medical Chemical Defense (ACD&P) – Program Funding [\$M] – 2004–2007.....   | 190 |

**12. Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|   |     |
|---|-----|
| Figure 111 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$B] – 2006–2010 .....             | 192 |
| Figure 112 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share – 2004, 2006 & 2010 .....     | 193 |
| Figure 113 - NIH (DHHS) – Nuclear/Radiological Countermeasures HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                    | 195 |
| Figure 114 - DOD – Nuclear/Radiological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                              | 196 |
| Figure 115 - DOE – Nuclear/Radiological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                              | 197 |
| Figure 116 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 199 |
| Figure 117 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 199 |
| Figure 118 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 200 |
| Figure 119 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 201 |
| Figure 120 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 201 |

Figure 121 - Project TR2 Medical Radiological Defense – Program Funding [\$M] – 2004–2007 ..... 205

Figure 122 - Project TR3 Medical Radiological Defense – Program Funding [\$M] – 2004–2011 ..... 206

Figure 123 - Project MR4 Medical Radiological Defense – Program Funding [\$M] – 2004–2011 ..... 207

Figure 124 - Low Dose Radiation Research – Program Funding [\$M] – 2004–2006 ..... 210

**13. Decontamination – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Figure 125 - Decontamination – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 ..... 213

Figure 126 - Decontamination– HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share – 2004, 2006 & 2010 ..... 213

Figure 127 - EPA – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 214

Figure 128 - DOD – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 215

Figure 129 - DHS – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 216

Figure 130 - DOE – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 217

Figure 131 - TSWG – Decontamination HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 218

Figure 132 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010..... 220

Figure 133 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010..... 220

Figure 134 - Decontamination HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 221

Figure 135 - Decontamination HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 222

Figure 136 - Decontamination HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 222

Figure 137 - Immune Buildings – Program Funding [\$M] – 2004-2007 ..... 226

Figure 138 - External Protection Funding [\$M] – 2004–2007 ..... 227

Figure 139 - Project CB1 – Decontamination – Program Funding [\$M] – 2004 – 2007 ..... 228

Figure 140 - Project CB2 – Decontamination – Program Funding [\$M] – 2004 – 2007 ..... 229

Figure 141 - Project CB3 Biological Defense (ATD) – Decontamination – Program Funding [\$M] – 2004 – 2007 ..... 229

Figure 142 - Project DE4 Decontamination Systems (ACD&P) – Program Funding [\$M] – 2004 – 2011 ..... 230

Figure 143 - Project DE5 Decontamination Systems (SDD) – Program Funding [\$M] – 2004 – 2011 ..... 231

Figure 144 - Industrial Operational Pollution Control Technology – Program Funding [\$M] – 2004 – 2007 ..... 234

Figure 145 - Military Medical Environment – Program Funding [\$M] – 2004 – 2007 ..... 235

Figure 146 - Pollution Prevention – Program Funding [\$M] – 2004 – 2007 ..... 236

Figure 147 - Base Facility Environmental Quality – Program Funding [\$M] – 2004 – 2007 ..... 236

Figure 148 - Environmental Remediation Science Research – Program Funding [\$M] – 2004–2006..... 238

**14. Diagnostics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Figure 149 - Diagnostics – HLS Pharmaceuticals R&D by Major Departments Budget Forecast [\$M] – 2006–2010..... 244

Figure 150 - Diagnostics – HLS Pharmaceuticals R&D by Major Departments Budget Forecast Share – 2004, 2006 & 2010..... 244

Figure 151 - DHHS – Diagnostics HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010..... 245

Figure 152 - DOD – Diagnostics HLS Pharmaceuticals R&D Budget Forecast – 2006–2010..... 246

Figure 153 - Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010..... 248

Figure 154 - Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010..... 248

Figure 155 - Diagnostics – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 249

Figure 156 - Diagnostics – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 249

Figure 157 - Diagnostics – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... 250

Figure 158 - Insect Vector Control and Infectious Disease – Diagnostics – Program Funding [\$M] – 2004–2007 ..... 253

Figure 159 – Advanced Diagnostic – Program Funding [\$M] – 2004–2007 ..... 254

Figure 160 - Project TB1 Medical Biological Defense (Basic Research) – Diagnostics – Program Funding [\$M] – 2004–2007 ..... 255

Figure 161 - Project TB2 Medical Biological Defense (Applied Research) – Diagnostics – Program Funding [\$M] – 2004–2007 ..... 256

Figure 162 - Project TB3 Medical Biological Defense (ATD) –Diagnostics – Program Funding [\$M] – 2004–2007 ..... 257

Figure 163 - Project MB5 Medical Biological Defense (SDD) – Diagnostics – Program Funding [\$M] – 2004–2007 ..... 258

Figure 164 - Project TC1 Medical Chemical Defense (Basic Research) – Diagnostics – Program Funding [\$K] – 2004–2007..... 259

Figure 165 - Project TC2 Medical Chemical Defense (Applied Research) – Diagnostics – Program Funding [\$M] – 2004–2007 ..... 260

Figure 166 - Project TC3 Medical Chemical Defense (ATD) – Diagnostics – Program Funding [\$K] – 2004–2007 ..... 261

**15. Food Protection Treatments – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Figure 167 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast – 2006–2010 ..... 264

Figure 168 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast Share – 2004, 2006 & 2010 ..... 264

Figure 169 - DHHS – Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010..... 265

Figure 170 - USDA – Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010..... 266

Figure 171 - DHS – Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010..... 267

Figure 172 - Food Protection Treatments – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 269

|  |     |
|--|-----|
| Figure 173 - Food Protection Treatments – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 269 |
| Figure 174 - Food Protection Treatments – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 270 |
| Figure 175 - Food Protection Treatments – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 271 |
| Figure 176 - Food Protection Treatments – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 272 |
| Figure 177 - Livestock Protection – Program Funding [\$M] – 2004–2007 .....  | 275 |

**16. Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Figure 178 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 .....             | 279 |
| Figure 179 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share – 2004, 2006 & 2010 .....     | 279 |
| Figure 180 - DHHS – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                             | 280 |
| Figure 181 - DOD – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                              | 281 |
| Figure 182 - DHS – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                              | 282 |
| Figure 183 - NSF – Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [\$M] – 2006–2010 .....                              | 283 |
| Figure 184 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....         | 285 |
| Figure 185 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector – 2004, 2006 & 2010 ..... | 285 |
| Figure 186 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....    | 286 |
| Figure 187 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [\$M] – 2006–2010 .....   | 287 |
| Figure 188 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [\$M] – 2006–2010 ..... | 287 |
| Figure 189 - Biological Adaptation, Assembly & Manufacture – Program Funding [\$M] – 2004-2007 .....   | 294 |
| Figure 190 - Nanostructure in Biology – Program Funding [\$M] – 2004–2007 .....  | 295 |
| Figure 191 - Project CB1 Biological Defense (Basic Research) – Other – Program Funding – 2004 – 2007 .....   | 295 |
| Figure 192 - Project TB2 Medical Biological Defense (Applied Research) – Emerging Threats – Program Funding [\$M] – 2004 – 2007 .....                      | 297 |
| Figure 193 - Project TB3 Medical Biological Defense (ATD) – Emerging Threats – Program Funding [\$M] – 2004 – 2007 .....                                   | 297 |
| Figure 194 - Project MB5 Medical Biological Defense (SDD) – Critical Reagents Program (CRP) – Program Funding [\$M] – 2004 – 2007 .....                    | 298 |
| Figure 195 - Project TC1 Medical Chemical Defense (Basic Research) – Emerging Threats – Program Funding [\$M] – 2004 – 2007 .....                          | 299 |
| Figure 196 - Non-Traditional Agents (NTAs) – Program Funding [\$M] – 2004 – 2007 .....   | 300 |
| Figure 197 - Project TC2 Medical Chemical Defense (Applied Research) – Emerging Threats – Program Funding [\$M] – 2004 – 2007 .....                        | 301 |
| Figure 198 - Project TC3 Medical Chemical Defense (ATD) – Emerging Threats – Program Funding [\$M] – 2004 – 2007 .....                                     | 301 |

Figure 199 - Project CB2 Chemical Defense (Applied Research) – Threat Agent  
Sciences – Program Funding [\$M] – 2004 – 2007 ..... 303

**Appendix A: The Homeland Security Federal R&D Infrastructure**

Figure 200 - Homeland Security Federal R&D General Structure ..... 307

## List of Tables

### 1. Executive Summary

|  |    |
|--|----|
| Table 1 - HLS Pharmaceuticals R&D - Participating Agencies Funding for FY 2006 [\$M] .....                     | 35 |
| Table 2 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [\$M] –<br>2006–2010.....                | 36 |
| Table 3 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [%] –<br>2006–2010.....                  | 36 |
| Table 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by<br>Sector [\$M] – 2006–2010 .....     | 39 |
| Table 5 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector<br>Share [%] – 2006–2010 ..... | 39 |

### 2. U.S. HLS Pharmaceuticals R&D Funding Opportunities – 2006 – 2010

|   |    |
|---|----|
| Table 6 - Major S&T Initiatives in the National Strategy for Homeland Security .....                            | 43 |
| Table 7 - HLS Pharmaceuticals R&D - Participating Agencies and Programs for<br>FY 2006-2010.....                | 47 |
| Table 8 – U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency [\$M] –<br>2006–2010.....              | 49 |
| Table 9 – U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency<br>Share [%] – 2006–2010 .....         | 49 |
| Table 10 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by<br>Sector [\$M] – 2006–2010 .....     | 52 |
| Table 11 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector<br>Share [%] – 2006–2010 ..... | 52 |

### 3. DHHS – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010

|   |    |
|---|----|
| Table 12 - DHHS – HLS Pharmaceuticals R&D Budget Forecast by Application [\$M] –<br>2006–2010.....                | 61 |
| Table 13 - DHHS – HLS Pharmaceuticals R&D Budget Forecast by Application<br>Share [%] – 2006–2010 .....           | 61 |
| Table 14 - DHHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast by<br>Sector [\$M] – 2006–2010 .....     | 64 |
| Table 15 - DHHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share<br>by Sector [%] – 2006–2010 ..... | 65 |

### 4. DOD – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010

|  |    |
|--|----|
| Table 16 - DOD – Research, Development, Test & Evaluation by Agency [\$B] –<br>2004–2006.....                    | 78 |
| Table 17 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Application [\$M] –<br>2006–2010.....                | 79 |
| Table 18 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Application<br>Share [%] – 2006–2010 .....           | 80 |
| Table 19 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Agency [\$M] –<br>2006–2010.....                     | 82 |
| Table 20 - DOD – HLS Pharmaceuticals R&D Budget Forecast by Agency Share [%] –<br>2006–2010.....                 | 82 |
| Table 21 - DOD – HLS Pharmaceuticals R&D Funding Opportunities Forecast by<br>Sector [\$M] – 2006–2010 .....     | 84 |
| Table 22 - DOD – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by<br>Sector [%] – 2006–2010 ..... | 84 |

**5. DHS – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

Table 23 - DHS – HLS Pharmaceuticals R&D Budget Forecast by Application [\$M] – 2006–2010..... 99

Table 24 - DHS – HLS Pharmaceuticals R&D Budget Forecast by Application Share [%] – 2006–2010 ..... 99

Table 25 - DHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 102

Table 26 - DHS – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 102

**6. DOE – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

Table 27 - DOE – HLS Pharmaceuticals R&D Funding Summary Forecast [\$M] – 2006–2010..... 108

Table 28 - DOE – HLS Pharmaceuticals R&D Funding Summary Forecast Share [%] – 2006–2010..... 109

Table 29 - DOE – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 110

Table 30 - DOE – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 111

**7. USDA – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

Table 31 - USDA – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 118

Table 32 - USDA – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 118

**8. EPA – HLS Pharmaceuticals R&D Funding Opportunities – 2006–2010**

Table 33 - EPA – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 126

Table 34 - EPA – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 126

**9. Biological Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Table 35 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 ..... 131

Table 36 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [%] – 2006–2010 ..... 131

Table 37 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010..... 135

Table 38 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010..... 135

**10. Vaccines – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Table 39 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 .....         | 148 |
| Table 40 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [%] – 2006–2010 .....           | 148 |
| Table 41 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....     | 152 |
| Table 42 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... | 152 |

**11. Chemical Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Table 43 - Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010.....     | 173 |
| Table 44 - Chemical Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010..... | 173 |

**12. Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|   |     |
|---|-----|
| Table 45 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 .....         | 192 |
| Table 46 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [%] – 2006–2010 .....           | 192 |
| Table 47 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....     | 198 |
| Table 48 - Nuclear/Radiological Therapeutics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... | 198 |

**13. Decontamination – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Table 49 - Decontamination – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [\$M] – 2006–2010 .....      | 212 |
| Table 50 - Decontamination – HLS Pharmaceuticals R&D Budget Forecast by Major Departments [%] – 2006–2010 .....        | 212 |
| Table 51 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010.....     | 219 |
| Table 52 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010..... | 219 |

**14. Diagnostics – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

|  |     |
|--|-----|
| Table 53 - Diagnostics – HLS Pharmaceuticals R&D by Major Departments Budget Forecast [\$M] – 2006–2010.....         | 243 |
| Table 54 - Diagnostics – HLS Pharmaceuticals R&D by Major Departments Budget Forecast Share [%] – 2006–2010.....     | 243 |
| Table 55 - Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [\$M] – 2006–2010 .....    | 247 |
| Table 56 - Diagnostics – HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [%] – 2006–2010..... | 247 |

**15. Food Protection Treatments – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Table 57 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments  
Forecast [\$M] – 2006–2010 ..... 263

Table 58 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments  
Forecast Share [%] – 2006–2010 ..... 263

Table 59 - Food Protection Treatments – HLS Pharmaceuticals R&D Funding  
Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 268

Table 60 - Food Protection Treatments – HLS Pharmaceuticals R&D Funding  
Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 268

**16. Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast – 2006–2010**

Table 61 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D  
Budget Forecast by Major Departments [\$M] – 2006–2010 ..... 278

Table 62 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D  
Budget Forecast by Major Departments Share [%] – 2006–2010 ..... 278

Table 63 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D  
Funding Opportunities Forecast by Sector [\$M] – 2006–2010 ..... 284

Table 64 - Treatment for Emerging Biochemical Threats – HLS Pharmaceuticals R&D  
Funding Opportunities Forecast Share by Sector [%] – 2006–2010 ..... 284

**Appendix A: The Homeland Security Federal R&D Infrastructure**

Table 65 - Small Business Innovation Research Program – FY2006 ..... 311

Table 66 - Small Business Technology Transfer Program – FY2006 ..... 314